EUVIMEDAtklāt EUVIMED
Open access · CC BY-NC 4.0

Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls

Seungyeop Baek, Jinny Claire Lee, Byung Hyun Byun, Su Yeon Park, Jeong Ho Ha, Kyo Chul Lee, Seung-Hoon Yang, Jun-Seok Lee, Seungpyo Hong, Gyoonhee Han, Sang Moo Lim, YoungSoo Kim and 1 more

Experimental Neurobiology · 2025-02-28 · 34 (1) · 1-8

DOI: 10.5607/en25008 ↗

At a glance

Journal article in Experimental Neurobiology, published on 2025-02-28. Written by Seungyeop Baek and 12 co-authors. Institution: Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea. Cited 4 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Korea Health Industry Development Institute, National Research Foundation of Korea, Yonsei University.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Alzheimer disease (AD) diagnosis is confirmed using a medley of modalities, such as the detection of amyloid-β (Aβ) neuritic plaques and neurofibrillary tangles with positron electron tomography (PET) or the appraisal of irregularities in cognitive function with examinations. Although these methods have been efficient in confirming AD pathology, the rising demand for earlier intervention during pathogenesis has led researchers to explore the diagnostic potential of fluid biomarkers in cerebrospinal fluid (CSF) and plasma. Since CSF sample collection is invasive and limited in quantity, biomarker detection in plasma has become more attractive and modern advancements in technology has permitted more efficient and accurate analysis of plasma biomolecules. In this study, we found that a composite of standard factors, Aβ40 and total tau levels in plasma, divided by the variation factor, plasma Aβ42 level, provide better correlation with amyloid neuroimaging and neuropsychological test results than a level comparison between total tau and Aβ42 in plasma. We collected EDTA-treated blood plasma samples of 53 subjects, of randomly selected 27 AD patients and 26 normal cognition (NC) individuals, who received amyloid-PET scans for plaque quantification, and measured plasma levels of Aβ40, Aβ42, and total tau with digital enzyme-linked immunosorbent assay (ELISA) in a blinded manner. There was difficulty distinguishing AD patients from controls when analyzing biomarkers independently. However, significant differentiation was observed between the two groups when comparing individual ratios of total-tau×Aβ40/Aβ42. Our results indicate that collectively comparing fluctuations of these fluid biomarkers could aid in monitoring AD pathogenesis.

Subjects

Author keywords

Alzheimer diseaseAmyloidBloodEnzyme-linked immunosorbent assayPlasmaTau

Authors and institutions

  • Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea.
  • Department of Nuclear Medicine, Korea Cancer Center Hospital, Seoul 01812, Korea.
  • Department of Neurology, Korea Cancer Center Hospital, Seoul 01812, Korea.
  • Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.
  • Department of Medical Biotechnology, Dongguk University, Seoul 04620, Korea.
  • Department of Pharmacology, Korea University, Seoul 02841, Korea.

Funding

  • Korea Health Industry Development Institute
  • National Research Foundation of Korea
  • Yonsei University

Cite

APA

Baek, S., Lee, J. C., Byun, B. H., Park, S. Y., Ha, J. H., Lee, K. C., Yang, S. H., Lee, J. S., Hong, S., Han, G., Lim, S. M., Kim, Y., & Kim, H. Y. (2025). Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls. Experimental Neurobiology, 34(1), 1-8. https://doi.org/10.5607/en25008

Vancouver

Baek S, Lee JC, Byun BH, Park SY, Ha JH, Lee KC, et al. Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls. Experimental Neurobiology. 2025;34(1):1-8. doi:10.5607/en25008

BibTeX
@article{Baek2025,
  author = {Baek, Seungyeop and Lee, Jinny Claire and Byun, Byung Hyun and Park, Su Yeon and Ha, Jeong Ho and Lee, Kyo Chul and Yang, Seung-Hoon and Lee, Jun-Seok and Hong, Seungpyo and Han, Gyoonhee and Lim, Sang Moo and Kim, YoungSoo and Kim, Hye Yun},
  title = {Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls},
  journal = {Experimental Neurobiology},
  year = {2025},
  volume = {34},
  number = {1},
  pages = {1--8},
  doi = {10.5607/en25008}
}
Start for free →